<DOC>
	<DOCNO>NCT00462852</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine , work different way stop growth tumor cell , either kill cell stop dividing . Anticoagulants , dalteparin , may help prevent blood clot form patient treated gemcitabine pancreatic cancer . PURPOSE : This randomized phase II trial study well gemcitabine work without dalteparin treat patient locally advance metastatic pancreatic cancer .</brief_summary>
	<brief_title>Gemcitabine With Without Dalteparin Treating Patients With Locally Advanced Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare incidence venous thromboembolism patient locally advance metastatic pancreatic cancer treat gemcitabine hydrochloride dalteparin versus gemcitabine hydrochloride alone . Secondary - Compare survival benefit , term increase ( 70 % 85 % ) survival 12 week , patient treat regimen . - Compare toxicity regimen . - Compare overall survival patient treat regimen . - Compare time disease progression patient treat regimen . - Determine effect gemcitabine hydrochloride dalteparin serological marker thromboangiogenesis . OUTLINE : This multicenter , randomize study . Patients stratify accord disease progression ( locally advance vs metastatic ) Karnofsky performance status ( ≥ 80 % v &lt; 80 % ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive gemcitabine hydrochloride IV 30 minute weekly week 1-7 9-11 . - Arm II : Patients receive low molecular weight dalteparin subcutaneously daily week 1-12 . Patients also receive gemcitabine hydrochloride arm I . Blood sample acquire baseline analysis circulate tissue factor vascular endothelial growth factor . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 120 patient accrue study .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm metastatic locally advanced adenocarcinoma pancreas Patients clinical 'high probability ' pancreatic cancer biopsy suggestive diagnostic pancreatic cancer may eligible base review principal investigator Measurable evaluable disease No clinical evidence active venous thromboembolism PATIENT CHARACTERISTICS : Karnofsky performance status ( PS ) 60100 % OR WHO PS 02 Life expectancy &gt; 12 week Absolute neutrophil count &gt; 2,000/mm³ WBC &gt; 3,000/mm³ Platelet count &gt; 100,000/mm³ Creatinine clearance &gt; 50 mL/min INR ≤ 1.5 time upper limit normal ( ULN ) Bilirubin &lt; 1.5 time ULN ( stent allow ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No cerebrovascular accident within past 6 month No obvious contraindication anticoagulation , include follow : Bleeding diathesis Active peptic ulcer Ulcerating cancer duodenum No history advance malignancy No gross hematuria No melaena gross evidence gastrointestinal bleeding ( pile ) No requirement central line No significant medial psychiatric illness , opinion investigator , would preclude study participation PRIOR CONCURRENT THERAPY : No prior gemcitabine hydrochloridecontaining treatment No concurrent cytotoxic chemotherapy , immunotherapy , hormonal therapy ( exclude contraceptive replacement steroid ) , experimental medication No concurrent specific anticancer therapy result disease progression No concurrent caval filter device No concurrent anticoagulant venous thromboembolism reason ( e.g. , atrial fibrillation ) No concurrent acetylsalicylic acid ( &gt; 75 mg ) antiplatelet drug preexist cardiovascular condition No concurrent clopidogrel bisulfate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>thromboembolism</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>stage II pancreatic cancer</keyword>
</DOC>